EGFR and cancer: Our findings indicate that CTX‐1 exhibits superior anticancer properties compared with the commonly used drug erlotinib, as indicated by its significant impact on decreasing cancer cell viability, instigating DNA damage, halting cell cycle progression, enhancing reactive oxygen species (ROS) production, altering mitochondrial transmembrane potential and inhibiting EGFR‐TKD.